ImmuCell Corporation (ICCC) Financial Statements (2025 and earlier)

Company Profile

Business Address 56 EVERGREEN DR
PORTLAND, ME 04103
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2509795,79210,1857,9468,774
Cash and cash equivalent2509795,79210,1856,9506,293
Short-term investments     9962,481
Receivables3,8122,1851,7592,6941,8481,637
Inventory, net of allowances, customer advances and progress billings7,1137,8126,0393,0902,0932,518
Inventory7,1137,8126,0393,0902,0932,518
Prepaid expense360 364 253218
Other current assets  58    
Other undisclosed current assets3,508 422951741
Total current assets:15,04311,03413,99516,26512,15713,189
Noncurrent Assets
Operating lease, right-of-use asset4,5614,5712,1951,1091,220 
Property, plant and equipment25,34927,57628,44226,89426,75525,266
Intangible assets, net (including goodwill)115134153172191210
Goodwill969696969696
Intangible assets, net (excluding goodwill)1938577696115
Other noncurrent assets3311,47077262627
Total noncurrent assets:30,05843,75030,86628,20128,19325,503
Other undisclosed assets  (10,976)    
TOTAL ASSETS:45,10043,80844,86144,46640,35038,692
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,4832,1242,0011,6141,3501,221
Taxes payable2  
Employee-related liabilities586525400
Accounts payable944888790745602572
Accrued liabilities1,5391,0441,0678285151
Other undisclosed accounts payable and accrued liabilities  19314419913798
Debt1,4981,4291,039812760 
Other undisclosed current liabilities432644321081011,275
Total current liabilities:4,4124,1973,0722,5342,2112,495
Noncurrent Liabilities
Long-term debt and lease obligation, including:9,04110,5409,1919,3549,8727,147
Long-term debt, excluding current maturities  9,1918,3278,7377,147
Other undisclosed long-term debt and lease obligation 9,04110,540    
Liabilities, other than long-term debt4,1294,0772,217  59
Operating lease, liability4,1294,0772,2171,0271,135 
Derivative instruments and hedges, liabilities      59
Other undisclosed noncurrent liabilities    (1,027)(1,135) 
Total noncurrent liabilities:13,17014,61811,4099,3549,8727,205
Total liabilities:17,58218,81514,48111,88912,0839,701
Equity
Equity, attributable to parent27,51824,99330,38032,57728,26628,991
Common stock904781781781730730
Treasury stock, value(138)(138)(147)(158)(175)(188)
Additional paid in capital40,91636,35735,97835,69231,37231,132
Accumulated other comprehensive loss      (44)
Accumulated deficit(14,164)(12,007)(6,232)(3,739)(3,660)(2,638)
Total equity:27,51824,99330,38032,57728,26628,991
TOTAL LIABILITIES AND EQUITY:45,10043,80844,86144,46640,35038,692

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues26,49317,47218,56819,24315,34213,723
Cost of revenue
(Cost of Product and Service Sold)
(18,552)(13,602)(10,919)(10,587)(8,479)(6,983)
Gross profit:7,9413,8697,6498,6566,8636,740
Operating expenses(9,581)(9,617)(9,948)(8,399)(8,243)(7,694)
Operating income (loss):(1,640)(5,748)(2,299)257(1,380)(954)
Nonoperating income (expense)(506)(22)(187)(327)348(314)
Other nonoperating income (expense) (22)(187)(327)348(314)
Interest and debt expense  (476)(349)(314)(8)(432)
Income (loss) from continuing operations before equity method investments, income taxes:(2,147)(6,246)(2,835)(383)(1,040)(1,699)
Other undisclosed income from continuing operations before income taxes  4763493148432
Income (loss) from continuing operations before income taxes:(2,147)(5,770)(2,486)(69)(1,032)(1,267)
Income tax expense (benefit)(10)(5)(8)(9)10(28)
Income (loss) from continuing operations:(2,157)(5,775)(2,494)(78)(1,022)(1,296)
Loss before gain (loss) on sale of properties:(78)(1,022)(1,296)
Net income (loss):(2,157)(5,775)(2,494)(78)(1,022)(1,296)
Net income attributable to noncontrolling interest   2,49478  
Other undisclosed net loss attributable to parent   (2,494)(78)  
Net income (loss) available to common stockholders, diluted:(2,157)(5,775)(2,494)(78)(1,022)(1,296)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(2,157)(5,775)(2,494)(78)(1,022)(1,296)
Other comprehensive income (loss)     44(74)
Comprehensive income (loss):(2,157)(5,775)(2,494)(78)(978)(1,370)
Comprehensive income, net of tax, attributable to noncontrolling interest   2,49478  
Other undisclosed comprehensive loss, net of tax, attributable to parent    (78)  
Comprehensive income (loss), net of tax, attributable to parent:(2,157)(5,775) (78)(978)(1,370)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: